Albany Molecular Research (NASDAQ:AMRI) was upgraded by equities research analysts at TheStreet from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Analyst Ratings.Net reports. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares after opening at $17.01 on last trade day and at the end of the day closed at $18.81. Company price to sales ratio in past twelve months was calculated as 2.45 and price to cash ratio as 15.20. Albany Molecular Research, Inc. (NASDAQ:AMRI) showed a positive weekly performance of 20.42%.
Chimerix Inc (NASDAQ:CMRX) issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. Chimerix Inc (NASDAQ:CMRX) shares advanced 2.80% in last trading session and ended the day on $27.14. CMRX return on equity ratio is recorded as 6.00% and its return on assets is 4.70%. Chimerix Inc (NASDAQ:CMRX) yearly performance is 77.12%.
Fate Therapeutics Inc (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − Prohema in UMbilical cord blood transplant in Adults) on Prohema. Prohema, the lead candidate at Fate Therapeutics, is a pharmacologically modified hematopoietic stem cell therapeutic derived from umbilical cord blood. The open-label, randomized, controlled multi-center study will evaluate the efficacy and safety of Prohema, when enhanced with a nutrient-rich media formulation (NRM formulation), in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) shares moved up27.14% in last trading session and was closed at $11.15, while trading in range of $8.70 – $12.81. Fate Therapeutics Inc (NASDAQ:FATE) year to date (YTD) performance is 77.55%.
March 13, 2014 — Xencor Inc (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update. Xencor Inc (NASDAQ:XNCR) weekly performance is 787%. On last trading day company shares ended up $57. Xencor Inc (NASDAQ:XNCR) distance from 50-day simple moving average (SMA50) is 757%. Analysts mean target price for the company is $89789.